Status:

UNKNOWN

Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)

Lead Sponsor:

Beijing Kawin Technology Share-Holding Co., Ltd.

Conditions:

Idiopathic Pulmonary Fibrosis

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of lung disease characterized by fibrosis of the supporting framework (interstitium) of the lungs. By definition, the term is used on...

Eligibility Criteria

Inclusion

  • Written informed consent signed;
  • 18-75 years of age;
  • Clinically or multidisciplinarily diagnosed idiopathic pulmonary fibrosis(see 2011 guidance );
  • Resting state PaO2≥50mg, FVC%≥45% normal predicted value and DLCO≥30% normal predicted value.

Exclusion

  • Allergic to pirfenidone;
  • Dyspnea symptoms relieved in the past 6 months;
  • Patients in acute exacerbation phase;
  • Diabetic patients whose fasting venous glucose \>11.1 mmol/L;
  • Patients with malignant tumor and hemorrhagic diseases;
  • Patients with serious underlying pulmonary disease;
  • Patients with serious heart disease(NYHA class Ⅲ-Ⅳ), liver disease(ALT or AST 2 times above the upper level of normal value range), kidney disease(Cr above the upper level of normal value range);
  • Patients who has taken Acetylcysteine in the past 3 months;
  • Patients who has taken Prednisone\>15mg/day(or other equivalent amount of glucocorticoid) and/or Immunosuppresants in the past 3 months;
  • Patients who has taken interferon, penicillamine, colchine or other agents for the treatment of IPF;
  • Pregnant or lactating women;
  • Participated in other clinical trials in the past 1 month;
  • The investigator assessed as inappropriate to participate in this clinical trial.

Key Trial Info

Start Date :

January 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2013

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT01504334

Start Date

January 1 2012

End Date

March 1 2013

Last Update

February 7 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking Union Medical College Hospital

Beijing, Beijng, China, 100032

Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF) | DecenTrialz